CanSino Biologics Inc.

The company was founded in 2009 in China. It is an industry-leading high-tech biological products company with the mission of providing solutions for the prevention and treatment of infectious diseases worldwide, focusing on the R&D, production and commercialization of innovative, high-quality, and accessible human vaccines. Cansino Biotech's mission has always been to “provide the world with innovative, high-quality, and accessible vaccines” to achieve the corporate vision of “endless innovation, a world free of diseases”. The company is an innovative vaccine enterprise dedicated to the development, production and commercialization of innovative vaccines that meet Chinese and international standards. The marketed products and product pipeline cover the prevention of meningitis, pneumonia, tuberculosis, COVID-19, Ebola virus disease, shingles, tuberculosis, and many other vaccine varieties with high clinical demand. The main products are MCV4, MCV2, AD5-nCoV, inhaled AD5-nCoV and xBB.1.5 variant vaccines, AD5-eBoV, etc. Corporate honors: National High-tech Enterprise, Tianjin Key Laboratory for Respiratory Bacterial Recombination and Combined Vaccine Enterprises, Nankai University Talent Training Cooperation and Development Base, Tianjin Model Group, etc.